Internal medicine

eClinicalWorks User Be Well Primary Care Medicine Adopts healow Sign, Reaching 95% Usage Among Patients

Retrieved on: 
Thursday, February 15, 2024

Be Well Primary Care Medicine PLLC is successfully leveraging healow® Sign, a healow patient engagement solution , to enhance the patient experience and streamline front office workflows.

Key Points: 
  • Be Well Primary Care Medicine PLLC is successfully leveraging healow® Sign, a healow patient engagement solution , to enhance the patient experience and streamline front office workflows.
  • The practice reports that over 95% of its patients now use healow Sign for faster check-in during office visits.
  • Be Well Primary Care specializes in internal medicine and preventive care services in Fort Worth, Texas.
  • “Our front desk sends consent forms electronically to patients before their appointments, saving time during check-in,” says Miriam Reyes, head of special projects at Be Well Primary Care Medicine.

New Chair and Executive Committee Members Appointed of Lymphoma Research Foundation Mantle Cell Lymphoma Consortium

Retrieved on: 
Thursday, February 15, 2024

NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – is pleased to announce Tycel Phillips, MD of City of Hope and Kami Maddocks, MD of Ohio State University to the Executive Committee members and Peter Martin, MD of Weill Cornell Medicine as Chair of its Mantle Cell Lymphoma Consortium (MCLC) Executive Committee.

Key Points: 
  • "LRF's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, CEO of the Lymphoma Research Foundation
    The Mantle Cell Lymphoma Consortium Executive Committee helps to guide the MCLC by identifying gaps in research and patient care for this historically understudied patient population.
  • Since its inception the Mantle Cell Lymphoma Consortium brings together leading international experts to discuss the latest research findings, foster collaboration within the mantel cell lymphoma (MCL) research community, create new directions for research, and ultimately improve diagnosis and treatment for this disease.
  • "The Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.
  • "I'm honored to lead this vital consortium dedicated to improving outcomes for all those impacted by mantle cell lymphoma," said Dr. Martin.

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors

Retrieved on: 
Thursday, February 15, 2024

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.

Key Points: 
  • Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.
  • Dr. Becker will serve as a member of the audit committee of the board.
  • View the full release here: https://www.businesswire.com/news/home/20240215803782/en/
    “I am excited that Dan has been appointed to our board,” said Jorge Bartolome, President and Chief Executive Officer of Areteia.
  • and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan and received his B.S.

Multi Board-Certified Physician Sam Setareh Opens MDVIP-Affiliated Primary Care Practice in Los Angeles

Retrieved on: 
Wednesday, February 14, 2024

LOS ANGELES and BOCA RATON, Fla., Feb. 14, 2024 /PRNewswire/ -- MDVIP, the market leader in personalized healthcare with a network of over 1,100 physicians nationwide, today announced the opening of a new MDVIP-affiliated internal medicine practice in Los Angeles. Sam Setareh, M.D., M.S., F.A.C.C., is currently accepting patients who want a more direct relationship with their primary care physician. Dr. Setareh brings an impressive and diversified background to MDVIP, including four board certifications in Internal Medicine, Cardiovascular Disease, Nuclear Cardiology and Echocardiology, and he is an attending physician at Cedars-Sinai Medical Center in Los Angeles.  Dr. Setareh serves as a member of multiple committees on the American College of Cardiology and the American Heart Association and as a founding member of the editorial board of The Journal of Scientific Innovation in Medicine.

Key Points: 
  • , is currently accepting patients who want a more direct relationship with their primary care physician.
  • Dr. Setareh brings an impressive and diversified background to MDVIP, including four board certifications in Internal Medicine, Cardiovascular Disease, Nuclear Cardiology and Echocardiology, and he is an attending physician at Cedars-Sinai Medical Center in Los Angeles.
  • "As an MDVIP-affiliated primary care physician, my mission is to help empower patients to take better control of their health through preventive medicine and highly individualized care," said Dr. Setareh, who has subspecialties in preventive cardiology, sports cardiology and advanced cardiovascular imaging.
  • He has treated and taken care of patients from all walks of life, including the most vulnerable to heads-of-state, dignitaries, athletes, celebrities and physician colleagues.

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.

Key Points: 
  • SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.
  • "We are delighted to welcome Dr. Johnson-Pratt to Aspen Neuroscience," said Damien McDevitt, PhD, Aspen Neuroscience president and chief executive officer.
  • "As we prepare to enter the clinic with our first-in-human trial for Parkinson's disease, we are deepening our investment in the company's development.
  • Lisa is a board director at Assembly Bio and Tracon Pharma, and is the board chair of Young People in Recovery.

Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors

Retrieved on: 
Monday, February 12, 2024

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.

Key Points: 
  • DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.
  • Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.
  • Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020.
  • "I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors.

Awaken Hope, Embrace Healing: The Multiple Sclerosis and Neuroimmune Summit 2.0

Retrieved on: 
Friday, February 9, 2024

CARLSBAD, Calif., Feb. 9, 2024 /PRNewswire/ -- DrTalks, a pioneering platform dedicated to advancing health, wellness, and medicine knowledge, is proud to announce Multiple Sclerosis and Neuroimmune Summit 2.0. This groundbreaking virtual event serves as an important platform for people grappling with multiple sclerosis and other neuroimmune conditions, offering a beacon of hope and a wealth of knowledge. Set to take place from August 20 to 26, 2024, this summit offers free online access to everyone interested in the latest breakthroughs in holistic and natural treatments for neuroimmune conditions.

Key Points: 
  • The Multiple Sclerosis and Neuroimmune Summit 2.0 is a premier virtual event that provides hope, knowledge, and support for people with multiple sclerosis and other neuroimmune conditions like lupus and rheumatoid arthritis.
  • CARLSBAD, Calif., Feb. 9, 2024 /PRNewswire/ -- DrTalks , a pioneering platform dedicated to advancing health, wellness, and medicine knowledge, is proud to announce Multiple Sclerosis and Neuroimmune Summit 2.0 .
  • This groundbreaking virtual event serves as an important platform for people grappling with multiple sclerosis and other neuroimmune conditions, offering a beacon of hope and a wealth of knowledge.
  • Dr. Wahls brings to the summit a unique perspective on neuroimmune conditions having been diagnosed with multiple sclerosis.

The Inner Circle Acknowledges, Furhan Qureshi as a Pinnacle Lifetime Member

Retrieved on: 
Thursday, February 8, 2024

ASHBURN, Va., Feb. 8, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Furhan Qureshi is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Pathology.

Key Points: 
  • ASHBURN, Va., Feb. 8, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Furhan Qureshi is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Pathology.
  • Dr. Qureshi pursued higher education at George Mason University where he earned a Bachelor of Science degree.
  • He then attended Ross University School of Medicine, graduating with a Doctor of Medicine degree in 2012.
  • A specialist in the field of internal medicine, Dr. Qureshi focuses his practice on the pathology of disease, diagnosis, and treatment.

agilon health Announces Chief Medical Officer Transition

Retrieved on: 
Thursday, February 8, 2024

agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to the company and will transition from his role as chief medical officer (CMO) effective March 1, 2024. agilon health has initiated a comprehensive search process to identify a new CMO.

Key Points: 
  • agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to the company and will transition from his role as chief medical officer (CMO) effective March 1, 2024. agilon health has initiated a comprehensive search process to identify a new CMO.
  • Dr. Rao and agilon’s chief clinical officer (CCO), Kevin Spencer, M.D., will co-lead the company’s clinical strategy.
  • He has built a strong team, and we are glad to have him continue as a valued advisor,” said Steve Sell, chief executive officer, agilon health.
  • Dr. Spencer received his medical degree from the University of Texas Health Science Center at Houston and completed his residency at the Carolinas Medical Center in North Carolina.

INTEGRATED ONCOLOGY NETWORK and cCARE WELCOME HEMATOLOGY ONCOLOGIST DR. PHILIP MARJON TO THEIR MEDICAL TEAM

Retrieved on: 
Thursday, February 8, 2024

NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with California Cancer Associates for Research & Excellence (cCARE) is thrilled to announce the addition of distinguished Hematology Oncologist Dr. Philip Marjon to the medical team. 

Key Points: 
  • NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with California Cancer Associates for Research & Excellence (cCARE) is thrilled to announce the addition of distinguished Hematology Oncologist Dr. Philip Marjon to the medical team.
  • We are excited to expand our team of expert medical professionals and enhance oncology care and support to our patients.
  • Philip Marjon, M.D., M.S., is a board-certified Hematologist and Medical Oncologist, having earned his medical degree from the University of New Mexico School of Medicine.
  • Dr. Marjon began his medical career as part of a research team with the University of New Mexico's Department of Biochemistry.